Cindy Eckert calls herself a crusader - in a pink suit.

She is on a mission to help women increase their sexual desire plus she created a fund to help female biotech startups.

So Alpha Rising thinks she's a crusader too. And we love the pink.

Eckert was CEO of Sprout Pharmaceuticals, the company that helped launch Addyi, a drug that addresses hypoactive (low) sexual desire disorder-a.k.a. HSDD -- in women.

Don't call it the female viagra because it is not the same.

She fought the FDA to finally get the drug approved in August 2015. A later, she she sold her company to Valeant for $1 billion in cash, thinking it would "march it across the world and get it into the hands of women who need it," says Eckert.

But that didn't happen.

Valeant fell apart was compared to Enron in some circles. Management went back on its promises and did nothing to get Addyi to the many women who needed it.

So Eckert took her company back - for nothing. And she's back in the CEO seat.

Oh, and she cut the price of Addyi in half.

So now she is crusading for the thousands of women with low sexual drive.

She also is crusading for female entrepreneurs. She took her billion dollars and started The Pink Ceiling, an incubator - a "pinkubator" to be exact - that helps female biotech startups.

She has ten in her portfolio right now.

She's looking for more.

So watch to the clip above and listen to Eckert's infectious enthusiasm. And check out the pink suit.

Watch the full conversation here:

We want to join the crusade.

And I, for one, love wearing pink.

More from Video

Biotech and Broadway Come Together to Fight Cancer

Biotech and Broadway Come Together to Fight Cancer

Market Movers: September Grain Stocks Report

Market Movers: September Grain Stocks Report

We Asked Our Pros About the Longevity of the Bull Market

We Asked Our Pros About the Longevity of the Bull Market

Legendary Technician Gives Her View of the Current Market

Legendary Technician Gives Her View of the Current Market

Cannabis: Why It May End Up in Your Portfolio

Cannabis: Why It May End Up in Your Portfolio